Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $7.6M | $9.5M | $9.2M | $8.6M | $6.7M | $5.8M | $6.5M |
| Cost of revenue | $2.2M | $2.6M | $3.6M | $3.7M | $3.9M | $3.4M | $3.1M | $3.4M |
| Gross profit | $3.2M | $4.9M | $5.9M | $5.5M | $4.8M | $3.3M | $2.7M | $3.2M |
| Gross margin | 58.8% | 65.4% | 62.0% | 60.2% | 55.2% | 49.1% | 47.0% | 48.7% |
| R&D | $1.0M | $1.0M | $1.3M | $1.2M | $1.2M | $925.0K | $1.5M | $1.3M |
| Operating income | −$797.0K | $364.0K | $236.0K | $698.0K | $111.0K | −$1.4M | −$2.2M | −$2.6M |
| EBITDA | −$659.0K | $323.0K | $1.3M | $1.3M | $750.0K | −$707.0K | −$1.9M | −$2.0M |
| Net income | −$668.0K | $432.0K | $952.0K | $1.5M | $1.0M | −$1.2M | −$2.0M | −$1.7M |
| Net margin | -12.4% | 5.7% | 10.0% | 16.5% | 11.9% | -17.7% | -34.7% | -25.3% |
| EPS (diluted) | -0.02 | 0.01 | 0.02 | 0.03 | 0.02 | -0.02 | -0.04 | -0.02 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2027 | $9M | $-0.01 | $-0.01–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
IXICO PLC ORD NEW
No one on the platform currently holds PHYOF.
No tracked institution reports a position in PHYOF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2018-10-02 | 100-for-1 |
| 2018-10-02 | 1-for-100reverse |
No one on the platform has traded PHYOF yet.
| $33M |
| — |
| MDXHFMedX Health Corp | $0.01 | -71.43% | $4M | — |
| NICXFNicox S.A. | $0.30 | +0.00% | $31M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.